Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 719-727

  Foody, Jo Anne M ^a   Toth, Peter P ^b,c   Tomassini, Joanne E ^d   Sajjan, Shiva ^d   Ramey, Dena R ^d   Neff, David ^d   Tershakovec, Andrew M ^d   Hu, Henry ^d   Tunceli, Kaan ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atorvastatin; Ezetimibe; Low density lipoprotein cholesterol goal; Rosuvastatin

Indexed keywords

ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DATA BASE; DRUG DOSE TITRATION; DRUG POTENCY; FEMALE; FOLLOW UP; GOAL ATTAINMENT; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; UNITED STATES;

ATORVASTATIN; EZETIMIBE; LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL; ROSUVASTATIN;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84889813405     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S49840     Document Type: Article

References (39)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010;376(9753): 1670-1681.
2. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3-46.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-732.
4. Foody JM, Sajjan SG, Hu XH, et al. Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients. J Clin Lipidol. 2010;4(2):126-132.
5. Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J. 2007;154(3):554-560.
6. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28-34.
7. Kauffman AB, Olson KL, Youngblood ML, et al. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. J Clin Lipidol. 2010;4(3):173-180.
8. Kitkungvan D, Lynn Fillipon NM, Dani SS, Downey BC. Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease. J Clin Lipidol. 2010;4(4):293-297.
9. Nag SS, Daniel GW, Bullano MF, et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 2007;13(8):652-663.
10. Catapano AL, Toth PP, Tomassini JE, Tershakovec AM. The efficacy and safety of ezetimibe co-administered with statin therapy in various patient groups. Clin Lipidol. 2012;8(1):13-41.
11. Toth PP, Ballantyne CM, Davidson MH et al. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012;6(2):180-191.
12. Crestor (rosuvastatin calcium) tablets [package insert]. Wilmington, DE: AstraZeneca; 2013.
13. Lipitor (atorvastatin calcium) tablets [package insert]. New York, NY: Pfizer; 2013.
14. Zocor (simvastatin) tablets [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2012.
15. Liptruzet (ezetimibe/atorvastatin) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2013.
16. Vytorin (ezetimibe/simvastatin) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2013.
17. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93(12):1487-1494.
18. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005;149(3):464-473.
19. Weinstock RS, Goldberg RB, Guyton JR et al. Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. J Clin Lipidol. 2008;2(1):25-35.
20. Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004;26(11):1758-1773.
21. Catapano AL, Davidson MH, Ballantyne CM et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22(10):2041-2053.
22. Pearson TA, Denke MA, McBride PE et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80(5):587-595.
23. Kosoglou T, Statkevich P, Yang B et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004;20(8):1185-1195.
24. Ballantyne CM, Weiss R, Moccetti T et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-680.
25. Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008;156(4):719-727.
26. Vande Griend JP, Saseen JJ. Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. J Clin Lipidol. 2009;3(3):195-200.
27. Toth PP, Catapano A, Tomassini JE, Tershakovec AM. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin Lipidol. 2010;5(5):655-684.
28. Aronow HD, Hess G, Hill J, Kuznik A, Liu LZ. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Am J Ther. 2010;17(2):167-175.
29. Atar D, Carmena R, Clemmensen P, et al. Clinical review: impact of statin substitution policies on patient outcomes. Ann Med. 2009;41(4): 242-256.
30. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. To switch (statins) or not to switch? That is the question. Expert Opin Pharmacother. 2010;11(18):2943-2946.
31. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-160.
32. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23(8):2009-2026.
33. Tunceli K, Sajjan SG, Ramey DR, et al. Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients. J Clin Lipidol. 2010;4(6):491-500.
34. Willey VJ, Bullano MF, Shoetan NN, Gandhi SK. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Curr Med Res Opin. 2010;26(1):121-128.
35. Karalis DG, Victor B, Ahedor L, Liu L. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol. 2012;2012:861924.
36. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159(5):705-709.
37. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192.
38. Holme I, Boman K, Brudi P, et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol. 2010;105(12):1802-1808.
39. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343-1356.